According to this report, these 4 drugs are at the top of the ladder, but as the report 
indicates, provided there are no stumbling blocks, which do come up, especially with the new practices in place at the FDA. In a related story, here’s another listing from Fierce Biotech listing “Emerging Drug Developers”, the weekly list of biotech companies who appear to be the most promising. Amgen still continues to be in the running in the midst of recent publicity and questions. BD
Motavizumab - AstraZeneca's MedImmune
Denosumab - Amgen
Golimumab - Johnson & Johnson's Centocor
Ipilimumab - Bristol-Myers Squibb, Medarex
Data courtesy of IMS Health
Denosumab, Ipilimumab, Goliumumab, Motavizumab - FierceBiotech
0 comments :
Post a Comment